NCT06249438View on ClinicalTrials.gov

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2040

Conditions
Systemic Lupus Erythematosus (SLE)Immune-mediated Necrotizing Myopathy (IMNM)Neuromyelitis Optica Spectrum Disorders (NMOSD)Multiple Sclerosis (MS)Myasthenia GravisSystemic Sclerosis (SSc)
Interventions
BIOLOGICAL

CD20/BCMA-directed CAR-T cells

Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously

Trial Locations (1)

200001

RECRUITING

Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai

Sponsors

Collaborators (1)

AbelZeta Pharma Inc.
All Listed Sponsors
collaborator

AbelZeta Pharma Inc.

UNKNOWN

lead

RenJi Hospital

OTHER

NCT06249438 - A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | Biotech Hunter | Biotech Hunter